Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Luminescence-based biosensor to non-invasively measure UBE3A activity in the brain

Award Number: R21NS142886
ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/19/2025
PERIOD OF PERFORMANCE END DATE: 02/28/2027

Group Awards By:

View Award Description

Luminescence-based biosensor to non-invasively measure UBE3A activity in the brain - SUMMARY Genetic mutations that alter UBE3A ubiquitin ligase activity are linked to several neurodevelopmental disorders. Angelman syndrome (AS) is a severe syndromic neurodevelopmental disorder that is caused by deletion or loss- of-function (LOF) mutation of the maternally inherited copy of UBE3A. In contrast, duplication of maternal or paternal UBE3A is associated with Dup15q syndrome, one of the most common forms of autism spectrum disorder. And gain-of-function (GOF) missense mutations in UBE3A cause neurodevelopmental phenotypes that are distinct from AS in humans and in mouse models. Therapeutics are being developed to increase or decrease UBE3A as treatments for AS and Dup15q, respectively. While reporter assays exist to evaluate UBE3A activity, these assays cannot be used to measure endogenous UBE3A activity in cells or in the brain non-invasively over time. This substantially limits the speed at which therapeutics that normalize UBE3A levels in vivo can be tested and advanced for these debilitating disorders. In preliminary studies, we developed a highly sensitive luciferase- based biosensor that can quantify endogenous UBE3A activity in cells and primary neurons. This biosensor can also quantify the spectrum of UBE3A activity associated with UBE3A LOF and GOF missense mutations. Here, we made additional modifications to the biosensor to improve its sensitivity to changes in UBE3A activity. We hypothesize that this biosensor with improved sensitivity can be used to quantify aberrant UBE3A activity in cells and in the brain of live animals that model various forms of autism. We propose to evaluate the efficacy of this UBE3A biosensor in primary cells (neurons, fibroblasts, blood cells) and in the brain of mouse lines that model AS (maternal Ube3a deficiency), Ube3a gene duplication, and an autism-linked Ube3a GOF mutation. We will also generate and validate a knock-in mouse harboring this UBE3A biosensor expressed from a neuron-specific promoter. This UBE3A biosensor knock-in mouse line could be used in future studies to non- invasively monitor the efficacy and durability of therapeutics that increase or decrease UBE3A activity, as respective treatments for AS and various forms of autism.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $194,375 )
2026	2026	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	104 AIRPORT DR STE 2200	CHAPEL HILL	NC	27599	ORANGE	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	2	2/25/2026	NON-COMPETING CONTINUATION	$194,375
														Subtotal = $194,375

Issue Date FY: 2025 ( Subtotal = $233,250 )
2025	2025	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	104 AIRPORT DR STE 2200	CHAPEL HILL	NC	27599	ORANGE	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	1	3/19/2025	NEW	$233,250
														Subtotal = $233,250

Grand Total All Awards = $427,625

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Luminescence-based biosensor to non-invasively measure UBE3A activity in the brain

Award Number: R21NS142886

ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/19/2025

PERIOD OF PERFORMANCE END DATE: 02/28/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer